Tag: capital

RENO, Nev., June 18, 2025 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA), (the “Company” or “Ormat”), a leading geothermal and renewable energy company, announced today that it has closed its previously disclosed acquisition of the Blue Mountain geothermal power plant from Cyrq Energy. Under the agreement, Ormat paid $88 million for 100% of the equity interest in the 20MW power plant.

DÜSSELDORF, Germany and ATLANTA, June 18, 2025 (GLOBE NEWSWIRE) -- Heramba Electric plc (OTC: PITEF) announced today the results of an extraordinary shareholder and board meeting held on June 3, 2025. More than 90.0%+ of shareholders voted on the following resolutions:

Statkraft, Europe's largest producer of renewable energy, will further strengthen its core competitive advantages by prioritising its flexible hydropower fleet in the Nordics, industry-leading market operations – and solar, wind and battery activities in Europe and South America. 

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

BORDEAUX, France, 18 juin 2025 (GLOBE NEWSWIRE) -- Financière Immobilière Bordelaise (410 312 110 RCS Bordeaux) (la « Société »), société holding du groupe éponyme spécialisé dans l’acquisition, la valorisation et la promotion d’actifs immobiliers (le « Groupe »), et émettrice d’obligations au titre d’un placement privé pour un montant nominal de 108 millions d’euros (ISIN FR0013479722) admises à la négociation sur Euronext Access (les « Obligations Euro PP »), annonce faire l’objet d’une procédure de redressement judiciaire ouverte, à sa demande, le 15 février 2023 par le Tribunal de commerce de Bordeaux.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.